Role of RNA‑binding protein 5 in the diagnosis and chemotherapeutic response of lung cancer (Review)
- Authors:
- Yanling Xu
- Zhenzhong Su
- Junyao Li
- Qi Wang
- Guangping Meng
- Yu Zhang
- Wen Yang
- Jie Zhang
- Peng Gao
-
Affiliations: Department of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, Changchun, Jilin 130041, P.R. China, Department of Geriatrics and General Medicine, The Second Affiliated Hospital of Jilin University, Changchun, Jilin 130041, P.R. China - Published online on: December 10, 2018 https://doi.org/10.3892/ol.2018.9818
- Pages: 2013-2019
This article is mentioned in:
Abstract
 |
|
Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
American Cancer Society, Cancer Facts & Figures, 2016. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2016.htmlJanuary 20–2018 | |
|
Carrato A, Vergnenègre A, Thomas M, McBride K, Medina J and Cruciani G: Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr Med Res Opin. 30:447–461. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hunt T and Nasmyth K: Cell multiplication. Curr Opin Cell Biol. 9:765–767. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Mueller BM, Yu YB and Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA. 92:205–209. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hirschi KK, Xu CE, Tsukamoto T and Sager R: Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary carcinoma cells and restore differentiation potential. Cell Growth Differ. 7:861–870. 1996.PubMed/NCBI | |
|
Sancar A: DNA repair in humans. Annu Rev Genet. 29:69–105. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Hanawalt PC: Transcription-coupled repair and human disease. Science. 266:1957–1958. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 9:541–573. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Ichihara S, Toyooka S, Fujiwara Y, Hotta K, Shigematsu H, Tokumo M, Soh J, Asano H, Ichimura K, Aoe K, et al: The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer. 120:1239–1247. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et al: Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 4:e74642009. View Article : Google Scholar : PubMed/NCBI | |
|
Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, et al: EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell. 154:1269–1284. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Menges CW, Kadariya Y, Altomare D, Talarchek J, Neumann-Domer E, Wu Y, Xiao GH, Shapiro IM, Kolev VN, Pachter JA, et al: Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res. 74:1261–1271. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K and Miyoshi S: Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg. 59:527–537. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Du J and Kwiatkowski DJ: Molecular dissection of AKT activation in lung cancer cell lines. Mol Cancer Res. 11:282–293. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, et al: A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2:685–693. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 16 Suppl 2:S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Suda K, Tomizawa K, Yatabe Y and Mitsudomi T: Lung cancers unrelated to smoking: Characterized by single oncogene addiction? Int J Clin Oncol. 16:294–305. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH and Yang PC: EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol. 7:98–104. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Paci M, Rapicetta C and Maramotti S: New biomarkers for lung cancer. Expert Opin Med Diagn. 4:201–224. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, Guarnera MA, Li R, Cai L, Zhan M and Jiang F: Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 11:3742011. View Article : Google Scholar : PubMed/NCBI | |
|
Claesson-Welsh L: Blood vessels as targets in tumor therapy. Ups J Med Sci. 117:178–186. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Timmer T, Terpstra P, van den Berg A, Veldhuis PM, Ter Elst A, Voutsinas G, Hulsbeek MM, Draaijers TG, Looman MW, Kok K, et al: A comparison of genomic structures and expression patterns of two closely related flanking genes in a critical lung cancer region at 3p21.3. Eur J Hum Genet. 7:478–486. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E and Nakamura Y: Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res. 59:1966–1972. 1999.PubMed/NCBI | |
|
Aravind L and Koonin EV: G-patch: A new conserved domain in eukaryotic RNA-processing proteins and type D retroviral polyproteins. Trends Biochem Sci. 24:342–344. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Drabkin HA, West JD, Hotfilder M, Heng YM, Erickson P, Calvo R, Dalmau J, Gemmill RM and Sablitzky F: DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC. Oncogene. 18:2589–2597. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Sutherland LC, Rintala-Maki ND, White RD and Morin CD: RNA binding motif (RBM) proteins: A novel family of apoptosis modulators? J Cell Biochem. 94:5–24. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Oh JJ, Razfar A, Delgado I, Reed RA, Malkina A, Boctor B and Slamon DJ: 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis. Cancer Res. 66:3419–3427. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Loiselle JJ and Sutherland LC: Differential downregulation of Rbm5 and Rbm10 during skeletal and cardiac differentiation. In Vitro Cell Dev Biol Anim. 50:331–339. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
O'Bryan MK, Clark BJ, McLaughlin EA, D'Sylva RJ, O'Donnell L, Wilce JA, Sutherland J, O'Connor AE, Whittle B, Goodnow CC, et al: RBM5 is a male germ cell splicing factor and is required for spermatid differentiation and male fertility. PLoS Genet. 9:e10036282013. View Article : Google Scholar : PubMed/NCBI | |
|
Bonnal S, Martinez C, Förch P, Bachi A, Wilm M and Valcárcel J: RBM5/Luca-15/H37 regulates Fas alternative splice site pairing after exon definition. Mol Cell. 32:81–95. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fushimi K, Ray P, Kar A, Wang L, Sutherland LC and Wu JY: Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5. Proc Natl Acad Sci USA. 105:15708–15713. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mourtada-Maarabouni M, Sutherland LC and Williams GT: Candidate tumour suppressor LUCA-15 can regulate multiple apoptotic pathways. Apoptosis. 7:421–432. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Sutherland LC, Lerman M, Williams GT and Miller BA: LUCA-15 suppresses CD95-mediated apoptosis in Jurkat T cells. Oncogene. 20:2713–2719. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Sutherland LC, Wang K and Robinson AG: RBM5 as a putative tumor suppressor gene for lung cancer. J Thorac Oncol. 5:294–298. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Wang K, Zhang J, Zhao L, Liang H, Shao C and Sutherland LC: The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin. Cancer Epidemiol. 36:481–489. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mourtada-Maarabouni M, Sutherland LC, Meredith JM and Williams GT: Simultaneous acceleration of the cell cycle and suppression of apoptosis by splice variant delta-6 of the candidate tumour suppressor LUCA-15/RBM5. Genes Cells. 8:109–119. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Rintala-Maki ND and Sutherland LC: LUCA-15/RBM5, a putative tumour suppressor, enhances multiple receptor-initiated death signals. Apoptosis. 9:475–484. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG and Visvader JE: Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene. 23:7726–7733. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sutherland LC, Edwards SE, Cable HC, Poirier GG, Miller BA, Cooper CS and Williams GT: LUCA-15-encoded sequence variants regulate CD95-mediated apoptosis. Oncogene. 19:3774–3781. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Kobayashi T, Ishida J, Musashi M, Ota S, Yoshida T, Shimizu Y, Chuma M, Kawakami H, Asaka M, Tanaka J, et al: p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. Int J Cancer. 128:304–318. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mourtada-Maarabouni M, Keen J, Clark J, Cooper CS and Williams GT: Candidate tumor suppressor LUCA-15/RBM5/H37 modulates expression of apoptosis and cell cycle genes. Exp Cell Res. 312:1745–1752. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shao C, Yang B, Zhao L, Wang S, Zhang J and Wang K: Tumor suppressor gene RBM5 delivered by attenuated Salmonella inhibits lung adenocarcinoma through diverse apoptotic signaling pathways. World J Surg Oncol. 11:1232013. View Article : Google Scholar : PubMed/NCBI | |
|
Shao C, Zhao L, Wang K, Xu W, Zhang J and Yang B: The tumor suppressor gene RBM5 inhibits lung adenocarcinoma cell growth and induces apoptosis. World J Surg Oncol. 10:1602012. View Article : Google Scholar : PubMed/NCBI | |
|
Su Z, Yin J, Zhao L, Li R, Liang H, Zhang J and Wang K: Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells. World J Surg Oncol. 12:3672014. View Article : Google Scholar : PubMed/NCBI | |
|
Rintala-Maki ND, Goard CA, Langdon CE, Wall VE, Traulsen KE, Morin CD, Bonin M and Sutherland LC: Expression of RBM5-related factors in primary breast tissue. J Cell Biochem. 100:1440–1458. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zabarovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 21:6915–6935. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Graveley BR: Alternative splicing: Increasing diversity in the proteomic world. Trends Genet. 17:100–107. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Nissim-Rafinia M and Kerem B: Splicing regulation as a potential genetic modifier. Trends Genet. 18:123–127. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Lo HS, Yang H, Gere S, Hu Y, Buetow KH and Lee MP: Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res. 63:655–657. 2003.PubMed/NCBI | |
|
Zhou Z, Licklider LJ, Gygi SP and Reed R: Comprehensive proteomic analysis of the human spliceosome. Nature. 419:182–185. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Jin W, Niu Z, Xu D and Li X: RBM5 promotes exon 4 skipping of AID pre-mRNA by competing with the binding of U2AF65 to the polypyrimidine tract. FEBS Lett. 586:3852–3857. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
U.S. Department of Health and Human Services: Smoking, Tobacco, and Cancer Program (1985–1989 Status Report). Public Health Service, USA. 1990. | |
|
Hecht SS: Cigarette smoking: Cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg. 391:603–613. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Harvey RG: Polycyclic aromatic hydrocarbons. Chemistry and Carcinogenicity. Cambridge University Press; Cambridge: pp. 3961991 | |
|
Beland FA, Cain LG, Felton JS, et al: Chemical Carcinogenesis and Mutagenesis I. Springer-Verlag. 33–572. 1990. | |
|
Bartsch H: DNA adducts in human carcinogenesis: Etiological relevance and structure-activity relationship. Mutat Res. 340:67–79. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Mass MJ, Jeffers AJ, Ross JA, Nelson G, Galati AJ, Stoner GD and Nesnow S: Ki-ras oncogene mutations in tumors and DNA adducts formed by benz[j]aceanthrylene and benzo[a]pyrene in the lungs of strain A/J mice. Mol Carcinog. 8:186–192. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Venkatachalam S, Denissenko MF, Alvi N and Wani AA: Rapid activation of apoptosis in human promyelocytic leukemic cells by (+/-)-anti-benzo[a]pyrene diol epoxide induced DNA damage. Biochem Biophys Res Commun. 197:722–729. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Denissenko MF, Pao A, Tang M and Pfeifer GP: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 274:430–432. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, Samet JM, Srivastava S, Minna JD and Gazdar AF: Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst. 89:1366–1373. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Jamsai D, Watkins DN, O'Connor AE, Merriner DJ, Gursoy S, Bird AD, Kumar B, Miller A, Cole TJ, Jenkins BJ, et al: In vivo evidence that RBM5 is a tumour suppressor in the lung. Sci Rep. 7:163232017. View Article : Google Scholar : PubMed/NCBI | |
|
Prabhu VV and Devaraj N: Regulating RNA binding Motif 5 gene expression-a novel therapeutic target for lung cancer. J Environ Pathol Toxicol Oncol. 36:99–105. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Canoz O, Ozkan M, Arsav V, Er O, Coskun HS, Soyuer S and Altinbas M: The role of c-erbB-2 expression on the survival of patients with small-cell lung cancer. Lung. 184:267–272. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hirsch FR, Franklin WA, Veve R, Varella-Garcia M and Bunn PA Jr: HER2/neu expression in malignant lung tumors. Semin Oncol. 29:51–58. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH and Park JY: EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet. 173:107–113. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Buttitta F, Barassi F, Fresu G, Felicioni L, Chella A, Paolizzi D, Lattanzio G, Salvatore S, Camplese PP, Rosini S, et al: Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer. 119:2586–2591. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hao YQ, Su ZZ, Lv XJ, Li P, Gao P, Wang C, Bai Y and Zhang J: RNA-binding motif protein 5 negatively regulates the activity of Wnt/β-catenin signaling in cigarette smoke-induced alveolar epithelial injury. Oncol Rep. 33:2438–2444. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lerman MI and Minna JD: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res. 60:6116–6133. 2000.PubMed/NCBI | |
|
Edamatsu H, Kaziro Y and Itoh H: LUCA15, a putative tumour suppressor gene encoding an RNA-binding nuclear protein, is down-regulated in ras-transformed Rat-1 cells. Genes Cells. 5:849–858. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B and Chang LS: cDNA microarray analysis of vestibular schwannomas. Otol Neurotol. 23:736–748. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao L, Li R, Shao C, Li P, Liu J and Wang K: 3p21.3 tumor suppressor gene RBM5 inhibits growth of human prostate cancer PC-3 cells through apoptosis. World J Surg Oncol. 10:2472012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YS, Hwan JD, Bae S, Bae DH and Shick WA: Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC Cancer. 10:5762010. View Article : Google Scholar : PubMed/NCBI | |
|
Peng J, Valeshabad AK, Li Q and Wang Y: Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features. Oncol Lett. 5:1000–1004. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Oh JJ, Taschereau EO, Koegel AK, Ginther CL, Rotow JK, Isfahani KZ and Slamon DJ: RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. Lung Cancer. 70:253–262. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, et al: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer. 103:153–160. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Bechara EG, Sebestyén E, Bernardis I, Eyras E and Valcárcel J: RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell. 52:720–733. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW III, Garner HR, McKay B, Latif F, et al: High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 60:1949–1960. 2000.PubMed/NCBI | |
|
Liang H, Zhang J, Shao C, Zhao L, Xu W, Sutherland LC and Wang K: Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. J Exp Clin Cancer Res. 31:362012. View Article : Google Scholar : PubMed/NCBI | |
|
Oh JJ, West AR, Fishbein MC and Slamon DJ: A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3. Cancer Res. 62:3207–3213. 2002.PubMed/NCBI | |
|
ter Elst A, Hiemstra BE, van der Vlies P, Kamminga W, van der Veen AY, Davelaar I, Terpstra P, te Meerman GJ, Gerbens F, Kok K, et al: Functional analysis of lung tumor suppressor activity at 3p21.3. Genes Chromosomes Cancer. 45:1077–1093. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ji L and Roth JA: Tumor suppressor FUS1 signaling pathway. J Thorac Oncol. 3:327–330. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Agathanggelou A, Bièche I, Ahmed-Choudhury J, Nicke B, Dammann R, Baksh S, Gao B, Minna JD, Downward J, Maher ER and Latif F: Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res. 63:5344–5351. 2003.PubMed/NCBI | |
|
Castro-Rivera E, Ran S, Thorpe P and Minna JD: Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci USA. 101:11432–11437. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Carboni GL, Gao B, Nishizaki M, Xu K, Minna JD, Roth JA and Ji L: CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity. Oncogene. 22:615–626. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE and Liu ET: Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: Correlation to human disease. Cancer Res. 64:5973–5981. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ramaswamy S, Ross KN, Lander ES and Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet. 33:49–54. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Loiselle JJ, Roy JG and Sutherland LC: RBM5 reduces small cell lung cancer growth, increases cisplatin sensitivity and regulates key transformation-associated pathways. Heliyon. 2:e002042016. View Article : Google Scholar : PubMed/NCBI | |
|
Loiselle JJ, Roy JG and Sutherland LC: RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5. PLoS One. 12:e01802582017. View Article : Google Scholar : PubMed/NCBI |
